The resolution of a high-profile clash over blood pressure tracking shows that tech companies cannot simply label clinical metrics as wellness tools to escape regulation.
For years, consumer wearables have crept into clinical territory. When Whoop introduced its “Blood Pressure Insights” feature, it triggered an immediate regulatory backlash. The FDA issued a warning letter in July 2025, classifying the feature as an unapproved medical device.
Whoop initially resisted, arguing the tool was merely for low-risk wellness. But the regulatory reality forced a pivot.
The Compromise
To resolve the dispute, Whoop had to make visual and labeling modifications to clarify the feature’s wellness purpose. Only then did the FDA close the warning letter in June 2026.
This compromise highlights a critical tension. Tech companies want to offer deep health insights to justify subscription fees. Yet, they must strip away clinical-sounding language to avoid strict medical device classification. The FDA’s updated general wellness guidance allowed Whoop to escape enforcement, but only after the company diluted its presentation.
The Real Impact
This case sets a clear boundary for the wearable industry. You can track biometric trends, but the moment you format those trends to mimic diagnostic tools, regulators will step in. The result is a bizarre paradox. Wearables are becoming more sophisticated, yet their user interfaces must remain intentionally vague to appease regulators.
For clinicians, this means patients will continue to bring in wearable data that lacks clinical context. The burden of translating “wellness insights” into actual medical decisions still falls entirely on the provider. Tech companies get to sell the hardware, while doctors inherit the messy data interpretation.
